AIDFAREL(TM) inhibits both the replication and transcription of the integrated viral DNA known as a provirus by using the drug technology termed Binary Molecular DNA Clamp (BMC). The drug consists of two similar but distinct parts that can be "programmed" to bind any specific Double Stranded DNA (dsDNA) sequence, in any gene. In CD4 T-cells infected with the virus, the drug is set to bind to where the tat and rev genes overlap. Once bound to the specified DNA sequence, the two parts react with each other to become one molecule that surrounds the target DNA molecular sequence, completely preventing transcription and translation of that region and shutting down all viral production permanently.
AIDFAREL(TM) is unique in that it only needs to be given three times over a one-month period, making the treatment process significantly less taxing for patients. Complete reconstitution of the immune system should occur within four to six weeks of the first intravenous injection of AIDFAREL(TM).
Binary Molecular DNA Clamp drug technology represents a promising new form
of anti-retroviral chemotherapy, for AIDS, other genetic disorders,
tissue-organ rejection and as a new laboratory tool in the study of molecular